Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 2/20 | 0.62 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HTR2B | P41595 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | ACP3 | P15309 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7873861 | 0.79 | IDO1 (0.47) | MIFHTR2AHTR2BHTR2CTAAR1 | |
| SCHEMBL46757 | 0.79 | HTR2A (0.63) | MIFHTR2AHTR2BHTR2CTAAR1 | |
| Ammonia Solution, Strong SCHEMBL266843 | 0.78 | HTR2A (0.61) | MIFHTR2AHTR2BHTR2CTAAR1 | |
| SCHEMBL121048 | 0.78 | TAAR1 (0.60) | MIFHTR2AHTR2BHTR2CTAAR1 | |
| SCHEMBL29824490 | 0.78 | TAAR1 (0.60) | MIFHTR2AHTR2BHTR2CTAAR1 | |
| SCHEMBL3237564 | 0.77 | TAAR1 (0.64) | MIFHTR2AHTR2BHTR2CTAAR1 | |
| SCHEMBL5103155 | 0.77 | TAAR1 (0.64) | MIFHTR2AHTR2BHTR2CTAAR1 | |
| SCHEMBL2489084 | 0.77 | MIF (0.71) | MIFHTR2AHTR2BHTR2CTAAR1 | |
| SCHEMBL7079916 | 0.77 | MIF (0.71) | MIFHTR2AHTR2BHTR2CTAAR1 | |
| SCHEMBL2340843 | 0.77 | MIF (1.00) | MIFHTR2AHTR2BHTR2CTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | claimed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | claimed |
| US-9597314-B2 | Beta-lactamylalkanoic acids for treating premenstrual disorders | AZEVAN PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | claimed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | claimed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | claimed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | claimed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11628160-B2 | Compositions and methods for treating brain injury | AZEVAN PHARMACEUTICALS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | AZEVAN PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200276167-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS INC (US) | 2020-09-03 | — | — | US | disclosed |
| US-5705513-A | HETEROCYCLIC FUNGICIDES WITH PYRIDINE OR FURAN RINGS | MONSANTO COMPANY (US) | 1998-01-06 | — | — | US | disclosed |
| US-5693667-A | Fungicides for the control of take-all disease of plants | MONSANTO COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0619297-B1 | Fungicides for the control of take-all desease of plants | MONSANTO CO (US) | 1997-06-18 | — | — | EP | disclosed |
| US-5498630-A | SUBSTITUTED BENZOTHIOPHENECARBOXAMIDES | MONSANTO COMPANY (US) | 1996-03-12 | — | — | US | disclosed |
| EP-0619297-A1 | Fungicides for the control of take-all desease of plants | MONSANTO COMPANY (US) | 1994-10-12 | — | — | EP | disclosed |
| WO-1993007751-A1 | FUNGICIDES FOR THE CONTROL OF TAKE-ALL DISEASE OF PLANTS | MONSANTO COMPANY (US) | 1993-04-29 | — | — | WO | disclosed |
| EP-0538231-A1 | Fungicides for the control of take-all disease of plants | MONSANTO COMPANY (US) | 1993-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | MIF 518/4885HTR2A 760/4885HTR2B 656/4885 |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | MIF 3990/4885HTR2A 1652/4885HTR2B 1921/4885 |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | GPX4, CRH, TXN | MIF 4621/4885HTR2A 376/4885HTR2B 397/4885 |
| US-20200276167-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | MIF 3990/4885HTR2A 1652/4885HTR2B 1921/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | MIF 4647/4885HTR2A 39/4885HTR2B 111/4885 |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | MIF 4647/4885HTR2A 39/4885HTR2B 111/4885 |
| US-11628160-B2 | Compositions and methods for treating brain injury | FABP7, PYGB, CHAT | MIF 3990/4885HTR2A 1652/4885HTR2B 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.